Business
Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform
Findings Anticipated to Unlock Broad New Commercial Opportunities Across Water-Soluble Drug ClassesMELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced positive preclinical results showing its proprietary gel formulation achieved substantially higher bioavailability than a leading on-market reference antihistamine product. In a comparative pharmac
About this update from Gelteq Limited
[{"type":"image","alt":"Gelteq Limited","displaySize":"","headline":null,"caption":"Gelteq Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/7b1e561b8eb101a1e67d96e6f6066b43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uXs2phR.sCaPuzjk7r6BAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7b1e561b8eb101a1e67d96e6f6066b43","width":300,"height":45}},"lazy":false},{"type":"text","content":"Findings Anticipated to Unlock Broad New Commercial Opportunities Across Water-Soluble Drug Classes","length":99,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced positive preclinical results showing its proprietary gel formulation achieved substantially higher bioavailability than a leading on-market reference antihistamine product.","length":376,"tagName":"p"},{"type":"text","content":"In a comparative pharmacokinetic study, Gelteq’s formulation demonstrated a 38–45% increase in systemic exposure and absorption (AUC) and markedly higher peak concentrations (Cmax), while maintaining a comparable time to peak plasma concentration (Tmax). The results of the study show Gelteq’s gel-based delivery technology can significantly enhance oral bioavailability of the drug, in addition to the broad benefits of the technology in solving drug delivery, swallowing and patient compliance issues.","length":503,"tagName":"p"},{"type":"text","content":"“These results represent a major technical and commercial milestone for Gelteq,” said Nathan Givoni, CEO of Gelteq. “A 38–45% improvement in bioavailability is transformative and validates our platform’s ability to meaningfully enhance the performance of established drugs. These results also position Gelteq to pursue a much broader portfolio of pharmaceutical opportunities where similar outcomes can be achieved via our proprietary gel-based delivery technology.”","length":466,"tagName":"p"},{"type":"text","content":"Importantly, the findings extend beyond the specific antihistamine evaluated in the study. Because the test compound is water-soluble, the demonstrated bioavailability improvement provi...